 |
|
New blood tests promise simple, cost-effective diagnosis of gastrointestinal cancers
September 21, 2009Berlin, Germany: Promising results from two new blood tests that can aid in the early identification of patients with gastrointestinal (GI) cancers will be presented at Europe's largest cancer congress, ECCO 15 - ESMO 34 [1], in Berlin today (Monday September 21). The tests will make GI cancer detection simpler, cost-effective, and more acceptable to patients than current methods, the researchers say.
In the first study, Dr Joost Louwagie, from the company OncoMethylome Sciences, headquartered in Liège, Belgium, will present data on the way in which tumour markers for colorectal cancer were selected, the analytical performance of the test and the first results from a multi-centre feasibility study. "This test has potential to provide a better balance of performance, cost-effectiveness and patient compliance than other options currently available for colorectal cancer screening," he says.
The scientists collected blood before surgery from 193 patients known to have colorectal cancer, as well as from 688 controls undergoing colonoscopy for cancer screening. DNA was extracted from the blood plasma and tested for the presence of DNA methylation of specific genes. DNA methylation is involved in the regulation of protein expression, and methylation or silencing of key genes has been linked to the initiation and progression of tumours. Based on studies conducted in colorectal tissues, methylated genes that were capable of discriminating accurately between cancerous and normal tissues were chosen. The scientists then evaluated the best-performing methylated genes in blood samples, with the ultimate goal of providing a sensitive, specific and patient-friendly option for colorectal cancer screening.
"We optimised the methods of DNA extraction and methylation detection so that we could detect low levels of methylated genes in people with colorectal cancer," says Dr Louwagie, "and we were able to find a high frequency of two newly reported methylation genes, SYNE1 and FOXE1, in colorectal cancer patients. The same methylation genes occurred infrequently in non-cancerous individuals."
When testing a first set of 444 controls and 124 colorectal cancer patients, with plasma volumes ranging between 0.8 and 4.3 ml, the sensitivity and specificity for the combination of SYNE1 and FOXE1 was 58% and 90% respectively. Testing this marker combination in a second, independent group of 242 controls and 69 cases, the sensitivity (proportion of positives correctly identified) and specificity (proportion of negatives correctly identified) were 56% and 91% respectively (77% and 91% in the samples with at least 3.3 ml of plasma). The sensitivity for stage I and II disease was 41% and 80% respectively.
Colorectal cancer occurs in approximately one in every 17 people during their lifetime and is the second leading cause of cancer death in the United States and Europe; in these places a combined total of about 560,000 people develop the disease each year, and 250,000 die from it. Deaths can be reduced if the cancer is diagnosed at an early stage, when it is most treatable. Although there are already two effective screening methods, they both have drawbacks.
Colonoscopy, where the interior of the colon and rectum is examined using a tiny camera mounted on a flexible tube, is the most sensitive test currently available and has the benefit of allowing removal of pre-cancerous polyps. Colonoscopy, however, is invasive, expensive, requires bowel preparation and skilled practitioners, making it inaccessible or unacceptable for many patients.
Faecal occult blood testing (FOBT), where patients give stool samples to be analysed, is less invasive, inexpensive and is used in national screening programmes in some European countries. However, due to patients' reluctance to handle stool samples, compliance for even the best-organised national screening programs is often less than 50%.
"Once validated in a prospective colorectal screening trial, the new methylation test could be used as a non-invasive screening option for patients who decline or do not have access to colonoscopy or do not wish to undertake the faecal occult blood test," says Dr Louwagie. "The blood sample can be taken by nurses or primary care doctors without the need for special equipment or training, leading to higher rates of patient compliance and the identification of patients needing the more expensive and diagnostic colonoscopy procedure. Giving such a blood sample could become part of the regular physical examination undertaken as part of a health insurance package in many countries."
The scientists are currently enrolling people into a prospective colorectal screening study in several German colonoscopy centres. "We plan to complete enrollment of 7000 people by the end of 2009," says Dr Louwagie "and are currently talking to several partners about distribution rights. This new test will not replace colonoscopy, but provide a way of screening a larger part of the population in a more patient-friendly and non-invasive manner so that more cancers are detected and treated successfully."
In a different study, researchers from Germany will say that they have developed another blood test that helps diagnose tumours in patients with colon, rectal, or gastric cancers. Professor Ulrike Stein, from the ECRC Charité University of Medicine, and the Max-Delbrueck-Centre for Molecular Medicine, both based in Berlin, says that the test can also predict the likelihood of metastatic disease in patients after diagnosis of these cancers.
Prof Stein and her team looked for the existence of an S100A4 transcript [2], by isolating RNA from blood plasma samples from patient with GI tumours. They collected daily blood samples from hospitalised and outpatients; 185 samples for colon cancer, 190 for rectal, and 91 for gastric cancer patients. They also analysed the blood of 51 age-matched, tumour-free volunteers.
"We found that S100A4 mRNA was present at significantly higher levels in the group of cancer patients, no matter whether they had colorectal or gastric cancer, than in the tumour-free control group," says Prof Stein, "and there were yet higher levels in the patients with metastases than in those where the disease had not yet metastasised. More importantly, prospective analysis of the data showed that follow-up patients who later developed metastases showed higher S100A4 levels at initial blood analysis than those whose disease did not metastasise. This means that in future we might be able to identify those patients who are likely to develop metastases."
Because the new test could be useful in identifying tumours in patients showing no signs of disease, it could be an effective tool in population screening for GI cancers. This needs to be tested in a large prospective trial, the researchers say. The S100A4 transcript was already known to promote the increased metastatic capability of cancer cells, but the problem to date has been that tests to establish its existence in a tumour have been expensive and complicated.
The scientists now intend to look at the correlation of S100A4 transcript levels in blood and the survival of individual patients after a minimum of three years follow-up. "We are hoping that, by enabling the identification of those patients whose disease is likely to progress more quickly, we will be able to treat them in the future accordingly by tailoring therapy to their individual needs," says Prof Stein.
###
Abstract nos: 12LBA (Louwagie) and 13LBA (Stein). Gastrointestinal malignancies, colorectal cancer 1, Monday 12.45 and 13.00 hrs CEST (Hall 2)
[1] ECCO 15 - ESMO 34 is the 15th congress of the European CanCer Organisation and the 34th congress of the European Society for Medical Oncology.
[2] Genetic transcription takes place when the information carried in DNA is copied into an RNA molecule, and is the first stage in the expression of a protein.
ECCO-the European CanCer Organisation
"We optimised the methods of DNA extraction and methylation detection so that we could detect low levels of methylated genes in people with colorectal cancer," says Dr Louwagie, "and we were able to find a high frequency of two newly reported methylation genes, SYNE1 and FOXE1, in colorectal cancer patients. The same methylation genes occurred infrequently in non-cancerous individuals."
When testing a first set of 444 controls and 124 colorectal cancer patients, with plasma volumes ranging between 0.8 and 4.3 ml, the sensitivity and specificity for the combination of SYNE1 and FOXE1 was 58% and 90% respectively. Testing this marker combination in a second, independent group of 242 controls and 69 cases, the sensitivity (proportion of positives correctly identified) and specificity (proportion of negatives correctly identified) were 56% and 91% respectively (77% and 91% in the samples with at least 3.3 ml of plasma). The sensitivity for stage I and II disease was 41% and 80% respectively.
Colorectal cancer occurs in approximately one in every 17 people during their lifetime and is the second leading cause of cancer death in the United States and Europe; in these places a combined total of about 560,000 people develop the disease each year, and 250,000 die from it. Deaths can be reduced if the cancer is diagnosed at an early stage, when it is most treatable. Although there are already two effective screening methods, they both have drawbacks.
Colonoscopy, where the interior of the colon and rectum is examined using a tiny camera mounted on a flexible tube, is the most sensitive test currently available and has the benefit of allowing removal of pre-cancerous polyps. Colonoscopy, however, is invasive, expensive, requires bowel preparation and skilled practitioners, making it inaccessible or unacceptable for many patients.
Faecal occult blood testing (FOBT), where patients give stool samples to be analysed, is less invasive, inexpensive and is used in national screening programmes in some European countries. However, due to patients' reluctance to handle stool samples, compliance for even the best-organised national screening programs is often less than 50%.
"Once validated in a prospective colorectal screening trial, the new methylation test could be used as a non-invasive screening option for patients who decline or do not have access to colonoscopy or do not wish to undertake the faecal occult blood test," says Dr Louwagie. "The blood sample can be taken by nurses or primary care doctors without the need for special equipment or training, leading to higher rates of patient compliance and the identification of patients needing the more expensive and diagnostic colonoscopy procedure. Giving such a blood sample could become part of the regular physical examination undertaken as part of a health insurance package in many countries."
The scientists are currently enrolling people into a prospective colorectal screening study in several German colonoscopy centres. "We plan to complete enrollment of 7000 people by the end of 2009," says Dr Louwagie "and are currently talking to several partners about distribution rights. This new test will not replace colonoscopy, but provide a way of screening a larger part of the population in a more patient-friendly and non-invasive manner so that more cancers are detected and treated successfully."
In a different study, researchers from Germany will say that they have developed another blood test that helps diagnose tumours in patients with colon, rectal, or gastric cancers. Professor Ulrike Stein, from the ECRC Charité University of Medicine, and the Max-Delbrueck-Centre for Molecular Medicine, both based in Berlin, says that the test can also predict the likelihood of metastatic disease in patients after diagnosis of these cancers.
Prof Stein and her team looked for the existence of an S100A4 transcript [2], by isolating RNA from blood plasma samples from patient with GI tumours. They collected daily blood samples from hospitalised and outpatients; 185 samples for colon cancer, 190 for rectal, and 91 for gastric cancer patients. They also analysed the blood of 51 age-matched, tumour-free volunteers.
"We found that S100A4 mRNA was present at significantly higher levels in the group of cancer patients, no matter whether they had colorectal or gastric cancer, than in the tumour-free control group," says Prof Stein, "and there were yet higher levels in the patients with metastases than in those where the disease had not yet metastasised. More importantly, prospective analysis of the data showed that follow-up patients who later developed metastases showed higher S100A4 levels at initial blood analysis than those whose disease did not metastasise. This means that in future we might be able to identify those patients who are likely to develop metastases."
Because the new test could be useful in identifying tumours in patients showing no signs of disease, it could be an effective tool in population screening for GI cancers. This needs to be tested in a large prospective trial, the researchers say. The S100A4 transcript was already known to promote the increased metastatic capability of cancer cells, but the problem to date has been that tests to establish its existence in a tumour have been expensive and complicated.
The scientists now intend to look at the correlation of S100A4 transcript levels in blood and the survival of individual patients after a minimum of three years follow-up. "We are hoping that, by enabling the identification of those patients whose disease is likely to progress more quickly, we will be able to treat them in the future accordingly by tailoring therapy to their individual needs," says Prof Stein.
###
Abstract nos: 12LBA (Louwagie) and 13LBA (Stein). Gastrointestinal malignancies, colorectal cancer 1, Monday 12.45 and 13.00 hrs CEST (Hall 2)
[1] ECCO 15 - ESMO 34 is the 15th congress of the European CanCer Organisation and the 34th congress of the European Society for Medical Oncology.
[2] Genetic transcription takes place when the information carried in DNA is copied into an RNA molecule, and is the first stage in the expression of a protein.
ECCO-the European CanCer Organisation
Colorectal Cancer Current Events and Colorectal Cancer News RSS'Cross-talk' mechanism contributes to colorectal cancer
Researchers at the University of Wisconsin-Madison School of Medicine and Public Health have identified a molecular mechanism that allows two powerful signaling pathways to interact and begin a process leading to colorectal tumors.
African-Americans with colorectal cancer have poorer outcomes, lower survival rates
New research published in the November issue of the Journal of the American College of Surgeons shows that African-American patients with colorectal cancer are more likely to be diagnosed with advanced disease and are less likely to undergo surgical procedures compared with Caucasians, suggesting that improvements in screening and rates of operation may reduce differences in colorectal cancer outcomes for African-Americans.
Colon cancer screening more effective earlier in day, UCLA study finds
The effectiveness of a screening colonoscopy may depend on the time of day it is performed. According to a new UCLA study, early-morning colonoscopies yielded more polyps per patient than later screenings, and fewer polyps were found hour by hour as the day progressed.
1 disease, not 1 demographic
The Asian continent has nearly four billion people living in 47 different countries, and each of these groups has their own unique set of health issues. But when they come to the United States, they're often lumped into one large demographic: "Asian/Pacific Islander."
Study shows unsedated colonoscopy for colorectal cancer screening well accepted by patients
Researchers from Taiwan report in a new study that unsedated colonoscopy for primary colorectal cancer screening is well accepted in a majority of patients.
M. D. Anderson redefines screening guidelines for breast, cervical and colorectal cancers
Drawing on years of experience in cancer research and patient care, The University of Texas M. D. Anderson Cancer Center released today the most comprehensive, risk-based screening guidelines publicly available to date for breast, cervical and colorectal cancers.
The bowels of infection
Current research suggests that latent cytomegalovirus (CMV) infection may exacerbate inflammatory bowel disease (IBD). The related report by Onyeagocha et al, "Latent cytomegalovirus infection exacerbates experimental colitis," appears in the November 2009 issue of The American Journal of Pathology.
How to Lower Costs, Waiting Times for Colonoscopies
Colorectal cancer is a leading cause of cancer-related deaths in the United States, leading to over 50,000 fatalities every year.
Excess body weight causes over 124,000 new cancers a year in Europe
At least 124,000 new cancers in 2008 in Europe may have been caused by excess body weight, according to estimates from a new modelling study.
Adding cetuximab to chemotherapy reduces advanced lung cancer death risk by 13 percent
Patients with advanced non-small cell lung cancer who are given cetuximab (Erbitux) in addition to chemotherapy are 13% less likely to die than those who receive chemotherapy alone, regardless of which chemotherapy drug cocktail is used, new research finds. They also experience slower disease progression and an increased chance of tumour shrinkage.
More Colorectal Cancer Current Events and Colorectal Cancer News Articles
 |
American Cancer Society's Complete Guide to Colorectal Cancer by American Cancer Society (Author) Don't die of embarrassment--get informed about colorectal cancer Although colorectal cancer is the third most common cancer found in men and women, you may be unaware of your risk and don't know what you can do to prevent this serious disease. You may be too embarrassed to ask your doctor about changes in your bowel habits or get screened for colorectal cancer. American Cancer Society's Complete Guide to Colorectal Cancer provides sound information and support if you are concerned about or diagnosed with colorectal cancer. Written by experts in oncology, nursing, research, and colorectal cancer care, the up-to-date, evidence-based text explores every aspect of colorectal cancer, from physical to emotional aspects of the disease, including: What colorectal... |
 |
Be a Survivor: Colorectal Cancer Treatment Guide by Vladimir Lange (Author) Dr. Lange’s comprehensive overview of cancer and treatment options offers detailed information using simple, concise language and a wide variety of color photos and drawings. Colorectal cancer patients need to know more about their disease, yet there is an overload of information. Be a Survivor gives the patient the specific, reliable and necessary information to make good decisions about their cancer and treatment options. Annually, 150,000 Americans are told they have colorectal cancer, making it one of the top three most common cancers in the United States. Diagnosed early, colorectal cancer is treatable, often curable, and vey preventable. This resource covers all aspects of colorectal cancer—from diagnosis to recovery, including a chapter for the patient's spouse. |
|
Progress in Colorectal Cancer by Mediscript | |
 |
New Tests, Treatments: Better Outcome for Colorectal Cancer Colorectal cancer is the third most common cancer and the second leading cause of cancer mortality in the U.S. Advances in imaging, genetics, molecular diagnostics, surgical techniques and chemotherapy are now making significant gains in our ability to prevent, diagnose, and treat this serious disease. Dr. Fisher reviews some of these recent successes and shares a vision of future care based on current research. |
 |
First Check Home ColoCheck Home Test, Colorectal Disease, 1 Test (Pack of 2) by First Check A First Check at 50 product. No specimen handling. No diet restrictions. FDA cleared. Fast. Accurate. Simple. A home test for the early warning signs of Colorectal Disease. Results in minutes. Early detection is key. First Check ColoCheck provides informa |
|
Screening for Colorectal Cancer: An Easy Step to Save Your Life (Three Real Patient Stories) Also With: American Digestive Health Foundation (Producer), Chuck Peet (Host) | |
 |
Colorectal Cancer Awareness Ribbon Mouse Pad by MyHeritageWear.com The Colorectal Cancer Ribbon proudly displayed on a mouse pad. There is no better way to achieve awareness for the meaning of the Colorectal Cancer Ribbon than to display it on your mouse pad for everyone to see. The mouse pad measures at 9.25 x 7.75, it is machine washable, and the colors will not fade or run. Start gaining awareness today by presenting your Colorectal Cancer Ribbon mouse pad at work or at home. It is certain to keep your mouse rolling in style all while gaining support and awareness! |
 |
Beating Colorectal Cancer Together Long Sleeve T-shirt Large White by Shop Zeus |
 |
Understanding Colorectal Cancer Anatomical Chart (Laminated) by Anatomical Chart Company Understanding Colorectal Cancer Anatomical Chart defines colorectal cancer and shows colorectal anatomy with the following pathologies: * Adenocarcinoma of colon * Circumferential carcinoma of the transverse colon * Colonic polyps * Adenocarcinoma of jejunum * Adenocarcinoma of the rectosigmoid region The chart describes risk factors, signs and symptoms, screening and diagnostic tests, and treatment options, and illustrates and explains the stages of cancer. |
 |
Beating Colorectal Cancer Together Keychain by Design a Product LLC Text on keychain: Beating Colorectal Cancer Together * Durable acrylic key chain is crystal-clear and double-sided so the artwork or message is seen twice. * Sturdy metal ring holds your keys securely. * Full color printed images or messages are included. * If you have new ideas or need help selecting text for your custom keychains please contact us. * Size: 2 1/8" x 3 1/2" (Approx. business card) |
| © 2009 BrightSurf.com |